ProMIS Neurosciences reported interim safety results from an amyloid-targeting Alzheimer’s trial suggesting a low rate of brain bleeding and no brain swelling, with results communicated ahead of additional clinical interpretation. The company said pooled safety data in a blinded analysis found ARIA at 4.4%, with only mild and asymptomatic ARIA events. Crucially for investors tracking tolerability, ProMIS reported no ARIA-E cases, the more severe ARIA subtype associated with swelling. Company framing implies a potential improvement over existing approved amyloid-targeting therapies that have been limited by ARIA risk. Market reaction in the associated coverage was described as muted, indicating that investors may be waiting for efficacy, duration, and robustness of the safety signal before repricing the program.